Search Results for: 153

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023

August 09, 2023 12:43 ET – Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Las segundas dosis de VCN-01 intravenoso administradas a pacientes en España fueron bien toleradas y presentaron un perfil de […]

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023 Read More »

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

August 08, 2023 08:00 ET – Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials – -VIRAGE remains on

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results Read More »

Our Science

The Theriva™ Difference Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy. The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and

Our Science Read More »

Theriva Home

DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS ABOUT THERIVA™ Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat

Theriva Home Read More »

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results Read More »

Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by

Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 Read More »

Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results

— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results Read More »

SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

— FDA Action Marks First Breakthrough Therapy Designation for Clinical Program Designed to Prevent Primary Clostridium difficile Infection — — Type-B Meeting Anticipated to Discuss Potential for Expedited Drug Development Strategy — ROCKVILLE, Md., May 11, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to

SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection Read More »